Trial Profile
Feasibility Study on Allogeneic Hematopoietic Stem Cell Transplantation Following Fludarabine-Busulfan-ALS-Based Reduced-Intensity Conditioning in Children With Hematological Malignancy or Solid Tumor Not Responding to Standard Therapy or for Which the Indication for Allograft is Maintained But Cannot be Carried Out Due to the Toxicity Involved in Myeloablative Conditioning.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Busulfan (Primary) ; Fludarabine (Primary)
- Indications Graft-versus-host disease; Haematological malignancies; Solid tumours
- Focus Therapeutic Use
- Acronyms RICE
- 26 Sep 2008 New trial record.